Home Men Health Men With Testicular Cancer May Have Latest Treatment Option

Men With Testicular Cancer May Have Latest Treatment Option

Men With Testicular Cancer May Have Latest Treatment Option

MONDAY, April 3, 2023 (HealthDay News) — Some patients with early testicular cancer may not need chemotherapy and radiation, researchers report.

As an alternative, surgery to remove lymph nodes in an area behind the abdomen lining called the retroperitoneum could also be enough, in accordance with their latest study.

“We found that the vast majority of participants within the study were cured with surgery alone, avoiding the toxicities related to traditional therapies. We’re confident that surgery for this disease state shall be included into treatment guidelines within the near future,” said lead investigator Dr. Sia Daneshmand, a urologic oncologist at Keck Medicine of the University of Southern California and a member of USC Norris Comprehensive Cancer Center.

Testicular cancer is usually treatable and mostly affects younger men, ages 15 to 35.

When it only spreads to the retroperitoneum, it is classed as early metastatic or stage 2 seminoma. Seminoma is a slow-growing form of testicular cancer.

Standard treatment is chemotherapy and radiation to shrink and kill the cancer within the lymph nodes, though when that fails, surgery is usually done. But surgery has not historically been used as a standalone treatment for this metastatic cancer.

Nonetheless, chemotherapy and radiation are related to long-term unwanted effects that include heart disease and secondary cancers.

To check the problem, the researchers enrolled 55 patients from 12 institutions.

Patients had previously undergone surgery to remove the testicle or testicles where the unique cancer occurred, and their cancer had progressed no further than to the retroperitoneum.

Once within the study, patients underwent removal of those lymph nodes by certified surgeons at participating institutions around the US and at one site in Canada.

About 81% of the patients were still freed from reoccurrence two years later. The 20% who had recurrent cancer were successfully treated with either chemotherapy or additional surgery for an overall survival rate of 100%.

“A 100% survival suggests that a cure can still be achieved even in patients who experience reoccurrence after the surgery,” Daneshmand noted in a Keck news release.

“Early metastatic seminoma has a really high survival rate; nevertheless, if treated with chemotherapy and radiation, the cure can come at a high cost,” he said. “Surgery gives patients each the chance to be cured and experience a top quality of life post-cancer.”

The findings were published recently within the Journal of Clinical Oncology.

More information

The American Cancer Society has more on testicular cancer.

SOURCE: Keck Medicine of USC, news release, March 30, 2023


Please enter your comment!
Please enter your name here